Akari Therapeutics Plc Stock Gross Profit
| AKTX Stock | USD 1.14 0.11 10.68% |
Akari Therapeutics PLC fundamentals help investors to digest information that contributes to Akari Therapeutics' financial success or failures. It also enables traders to predict the movement of Akari Stock. The fundamental analysis module provides a way to measure Akari Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Akari Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Gross Profit | -4 K | -4.2 K |
Akari | Gross Profit |
Akari Therapeutics PLC Company Gross Profit Analysis
Akari Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Akari Therapeutics Gross Profit | (4.2K) |
Most of Akari Therapeutics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Akari Therapeutics PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Akari Gross Profit Driver Correlations
Understanding the fundamental principles of building solid financial models for Akari Therapeutics is extremely important. It helps to project a fair market value of Akari Stock properly, considering its historical fundamentals such as Gross Profit. Since Akari Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Akari Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Akari Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
Akari Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Akari Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Akari Therapeutics could also be used in its relative valuation, which is a method of valuing Akari Therapeutics by comparing valuation metrics of similar companies.Akari Therapeutics is currently under evaluation in gross profit category among its peers.
Akari Fundamentals
| Return On Equity | -12.81 | ||||
| Return On Asset | -1.73 | ||||
| Current Valuation | 24.26 M | ||||
| Shares Outstanding | 20.65 M | ||||
| Shares Owned By Insiders | 11.90 % | ||||
| Shares Owned By Institutions | 0.50 % | ||||
| Number Of Shares Shorted | 21.29 K | ||||
| Price To Earning | (2.15) X | ||||
| Price To Book | 3.07 X | ||||
| EBITDA | (16.8 M) | ||||
| Net Income | (10.01 M) | ||||
| Cash And Equivalents | 8.15 M | ||||
| Cash Per Share | 0.14 X | ||||
| Total Debt | 4.58 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.73 X | ||||
| Book Value Per Share | (0.04) X | ||||
| Cash Flow From Operations | (16.43 M) | ||||
| Short Ratio | 1.92 X | ||||
| Earnings Per Share | (2.58) X | ||||
| Target Price | 80.0 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 30.35 M | ||||
| Total Asset | 4.36 M | ||||
| Retained Earnings | (227.46 M) | ||||
| Working Capital | 1.77 M | ||||
| Current Asset | 69.66 M | ||||
| Current Liabilities | 21.12 M | ||||
| Net Asset | 4.36 M |
About Akari Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Akari Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akari Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akari Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.